Eagle Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Eagle Pharmaceuticals
EGRX Stock  USD 0.25  0.00  0.00%   
Eagle Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Eagle Pharmaceuticals' valuation are provided below:
Gross Profit
179.9 M
Profit Margin
0.0464
Market Capitalization
3.3 M
Enterprise Value Revenue
0.3789
Revenue
257.6 M
We have found one hundred twenty available fundamental signals for Eagle Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Eagle Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 500.4 M in 2026. Enterprise Value is likely to rise to about 467.4 M in 2026

Eagle Pharmaceuticals Total Revenue

382.31 Million

Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many indicators such as Price To Sales Ratio of 1.3, Dividend Yield of 0.0 or PTB Ratio of 1.77. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Eagle Stock
Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

Eagle Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets490.4 M467.1 M228.5 M
Slightly volatile
Short and Long Term Debt Total43.2 M78 M43.5 M
Slightly volatile
Other Current Liabilities95.5 M91 M33.9 M
Slightly volatile
Total Current Liabilities134.1 M127.8 M59.1 M
Slightly volatile
Property Plant And Equipment Net2.3 M1.3 M1.8 M
Pretty Stable
Current Deferred Revenue17.3 M29.2 M17.5 M
Slightly volatile
Accounts Payable22.9 M21.8 M10.6 M
Slightly volatile
Cash73 M63.6 M58.1 M
Slightly volatile
Non Current Assets Total262.5 M250 M98.5 M
Slightly volatile
Non Currrent Assets Other19 M18.1 M6.2 M
Slightly volatile
Other Assets63.9 M60.8 M24.4 M
Slightly volatile
Cash And Short Term Investments75.1 M63.6 M59.6 M
Slightly volatile
Net Receivables88.7 M84.5 M43.5 M
Slightly volatile
Common Stock Total Equity15.2 K20.7 K13.3 K
Slightly volatile
Common Stock Shares Outstanding14.9 M15 M13.3 M
Slightly volatile
Liabilities And Stockholders Equity490.4 M467.1 M228.5 M
Slightly volatile
Non Current Liabilities Total74.3 M70.7 M31 M
Slightly volatile
Inventory57.7 M55 M19.2 M
Slightly volatile
Other Current Assets12.1 M14 M10.2 M
Slightly volatile
Other Stockholder Equity121.6 M141.6 M101.8 M
Slightly volatile
Total Liabilities208.4 M198.5 M88.9 M
Slightly volatile
Property Plant And Equipment Gross9.4 M8.9 M4.1 M
Slightly volatile
Total Current Assets137 M217.1 M124.7 M
Slightly volatile
Short Term Debt8.9 M9 M8 M
Pretty Stable
Common Stock15.2 K20.7 K13.3 K
Slightly volatile
Property Plant Equipment2.3 M1.3 M1.8 M
Pretty Stable
Other Liabilities3.2 M3.4 M11 M
Slightly volatile
Net Tangible Assets106.8 M80.7 M78.5 M
Slightly volatile
Capital Surpluse282.9 M421.2 M253 M
Slightly volatile
Non Current Liabilities Other5.1 M4.8 M11.4 M
Slightly volatile
Long Term Debt Total43.1 M64.6 M45.5 M
Slightly volatile
Net Invested Capital250.6 M340.4 M243.4 M
Slightly volatile
Short and Long Term Debt10.3 M7.2 M7.1 M
Slightly volatile
Net Working Capital94.7 M69.9 M118.8 M
Slightly volatile
Capital Stock18.9 K20.7 K17.5 K
Slightly volatile
Capital Lease Obligations4.5 M6.1 M3.8 M
Slightly volatile

Eagle Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization14.5 M13.8 M5.2 M
Slightly volatile
Interest Expense4.9 M4.7 M2 M
Slightly volatile
Selling General Administrative118.5 M112.8 M59 M
Slightly volatile
Total Revenue382.3 M364.1 M176.3 M
Slightly volatile
Other Operating Expenses284.5 M271 M142.2 M
Slightly volatile
Research Development32.8 M39.2 M29 M
Slightly volatile
Cost Of Revenue114.6 M109.2 M51.5 M
Slightly volatile
Total Operating Expenses89 M161.8 M85.9 M
Slightly volatile
Selling And Marketing Expenses6.2 M9.8 M5.9 M
Slightly volatile
Preferred Stock And Other Adjustments1.3 M1.5 M1.6 M
Slightly volatile
Interest Income537.5 K311.6 K315.9 K
Slightly volatile
Non Recurring13.7 M8.5 M13.1 M
Very volatile
Reconciled Depreciation14.5 M13.8 M6.5 M
Slightly volatile

Eagle Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation13.2 M18.9 M11.7 M
Slightly volatile
Begin Period Cash Flow65.2 M63.6 M53.4 M
Slightly volatile
Depreciation20.1 M19.2 M6.6 M
Slightly volatile
Capital Expenditures152.2 K160.2 K1.8 M
Pretty Stable
End Period Cash Flow70.5 M35.4 M51.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.31.3711.4438
Slightly volatile
Days Sales Outstanding12997.36121
Slightly volatile
Stock Based Compensation To Revenue0.06480.04680.078
Slightly volatile
Capex To Depreciation0.01620.0172.9138
Slightly volatile
EV To Sales1.351.4211.2561
Slightly volatile
Inventory Turnover2.172.289.06
Slightly volatile
Days Of Inventory On Hand174165126
Slightly volatile
Payables Turnover4.084.54.7586
Slightly volatile
Sales General And Administrative To Revenue0.250.280.2896
Slightly volatile
Average Inventory783.1 K881 K961.6 K
Slightly volatile
Research And Ddevelopement To Revenue0.120.10770.8379
Slightly volatile
Capex To Revenue6.0E-46.0E-40.0137
Slightly volatile
Cash Per Share3.983.854.5293
Slightly volatile
Days Payables Outstanding97.2283.9891.5202
Slightly volatile
Intangibles To Total Assets0.210.360.3087
Pretty Stable
Current Ratio2.31.532.5221
Pretty Stable
Receivables Turnover2.743.883.3577
Slightly volatile
Capex Per Share0.0150.01580.1267
Pretty Stable
Average Receivables2.7 M3 M3.3 M
Slightly volatile
Revenue Per Share23.1322.0312.6239
Slightly volatile
Interest Debt Per Share5.255.02.5643
Slightly volatile
Debt To Assets0.30.190.2632
Slightly volatile
Graham Number18.2230.1219.5233
Slightly volatile
Operating Cycle236309245
Very volatile
Days Of Payables Outstanding97.2283.9891.5202
Slightly volatile
Long Term Debt To Capitalization0.190.220.1883
Very volatile
Quick Ratio2.141.142.2879
Very volatile
Net Income Per E B T1.060.670.9085
Pretty Stable
Cash Ratio0.430.451.2879
Pretty Stable
Cash Conversion Cycle101176149
Very volatile
Days Of Inventory Outstanding174165126
Slightly volatile
Days Of Sales Outstanding12997.36121
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.071.151.0054
Very volatile
Fixed Asset Turnover256244114
Slightly volatile
Debt Ratio0.30.190.2632
Slightly volatile
Price Sales Ratio1.31.3711.4438
Slightly volatile
Asset Turnover0.550.70.6558
Slightly volatile

Eagle Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap500.4 M340.3 M586.2 M
Very volatile
Enterprise Value467.4 M351.5 M555.2 M
Very volatile

Eagle Fundamental Market Drivers

Forward Price Earnings11.3379
Cash And Short Term Investments55.3 M

Eagle Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About Eagle Pharmaceuticals Financial Statements

Eagle Pharmaceuticals investors use historical fundamental indicators, such as Eagle Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue29.2 M17.3 M
Total Revenue364.1 M382.3 M
Cost Of Revenue109.2 M114.6 M
Stock Based Compensation To Revenue 0.05  0.06 
Sales General And Administrative To Revenue 0.28  0.25 
Research And Ddevelopement To Revenue 0.11  0.12 
Revenue Per Share 22.03  23.13 
Ebit Per Revenue 0.23  0.24 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Eagle Stock Analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY